Sartorius Stedim Biotech Signs Agreement With WuXi AppTec, Inc.

AUBAGNE, France & GOETTINGEN, Germany & ST. PAUL, Minn.--(BUSINESS WIRE)--Sartorius Stedim Biotech (Paris:DIM) has entered into an agreement with WuXi AppTec, Inc., a wholly owned operating subsidiary of WuXi PharmaTech (NYSE:WX), to cooperate on viral clearance studies. Under this agreement, WuXi AppTec will provide the relevant viruses, materials and methodologies to Sartorius Stedim Biotech to employ in conducting non GLP viral clearance testing of its technologies with customer products and for supporting its own research and development activities.

Back to news